help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by MELLÉN, A.
Right arrow Articles by LÖTVALL, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by MELLÉN, A.
Right arrow Articles by LÖTVALL, J.

Am. J. Respir. Crit. Care Med., Volume 159, Number 5, May 1999, 1663-1665

Equivalent Bronchodilation with Salbutamol Given via pMDI or Turbuhaler

ANDERS MELLÉN, PETER ARVIDSSON, MONA PALMQVIST, and JAN LÖTVALL

Department of Respiratory Medicine and Allergology, and Department of Clinical Pharmacology, Göteborg University, Sahlgrenska University Hospital, Gothenburg, Sweden

Several breath-activated multidose powder devices for inhaled anti-asthma drugs are now available. Some of these inhalers have been argued to give higher drug deposition in the airways than conventional pressurized metered dose inhalers (pMDI). The aim of the present study was to compare the efficacy and safety of salbutamol given via pMDI or Turbuhaler (both 100 µg per inhalation). Adult asthmatic patients of either sex (n = 22) and with reversible airflow obstruction were included in a randomized, placebo-controlled study. On the study days, salbutamol was given with increasing doses (200 to 3,200 µg cumulative) or placebo, via pMDI or Turbuhaler. A dose-related increase in FEV1 was observed after administration of salbutamol given via either device, versus placebo. The improvement in FEV1 was similar whether salbutamol was given via pMDI or Turbuhaler, at microgram equivalent doses. After a total cumulative dose of 3,200 µg, mean FEV1 for Turbuhaler was 2.98 (change from baseline of 23.1%), for pMDI 2.93 (change from baseline of 23.6%), and for placebo 2.36 (change from baseline of 0.42%). Changes in potassium, glucose, and heart rate did not show any significant differences between pMDI and Turbuhaler. We conclude that the efficacy of salbutamol is comparable when the drug is given via the Turbuhaler or pMDI.




This article has been cited by other articles:


Home page
 CMAJHome page
Inhalation devices
Can. Med. Assoc. J., September 13, 2005; 173(6_suppl): S39 - S45.
[Full Text] [PDF]

Home page
 BMJHome page
F. S F Ram, J. Wright, D. Brocklebank, and J. E S White
Systematic review of clinical effectiveness of pressurised metered dose inhalers versus other hand held inhaler devices for delivering beta 2 agonists bronchodilators in asthma
BMJ, October 20, 2001; 323(7318): 901 - 901.
[Abstract] [Full Text]

Home page
 Am. J. Respir. Crit. Care Med.Home page
D. FISHWICK, L. BRADSHAW, C. MACDONALD, R. BEASLEY, D. GASH, T. BENGTSSON, E. BONDESSON, and L. BORGSTRÖM
Cumulative and Single-dose Design to Assess the Bronchodilator Effects of {beta}2-Agonists in Individuals with Asthma
Am. J. Respir. Crit. Care Med., February 1, 2001; 163(2): 474 - 477.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 1999 American Thoracic Society